[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338068-105":59,"doc-detail-338068-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","itgb6-modulates-resistance-to-anti-cd276-therapy-in-head-and-neck-cancer-by-promoting-pf4-macrophage-infiltration","ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration","","ITGB6 is identified as a key determinant of differential response to anti-CD276 antibodies in head and neck squamous cell carcinoma using chemically-induced and orthotopic mouse models. Single-cell RNA sequencing and gene knockout models show ITGB6 controls CX3CL1 expression, driving recruitment and activation of CX3CR1-high PF4+ macrophages. Blocking the CX3CL1–CX3CR1 axis reduces CXCL16 infiltration and secretion, reinvigorating CXCR6+ CD8+ T cells and restoring sensitivity to anti-CD276 treatment, including resistance to PD1 antibodies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/itgb6-modulates-resistance-to-anti-cd276-therapy-in-head-and-neck-cancer-by-promoting-pf4-macrophage-infiltration/338068/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/itgb6-modulates-resistance-to-anti-cd276-therapy-in-head-and-neck-cancer-by-promoting-pf4-macrophage-infiltration/338068.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in anti-CD276 treatment for head and neck cancer?","Question",{"text":112,"@type":113},"The study addresses a non-responsive population to anti-CD276 therapy in mouse models, where the resistance mechanisms were unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers identify ITGB6 as relevant to anti-CD276 resistance?",{"text":117,"@type":113},"They used induced and orthotopic carcinogenesis models, then applied single-cell RNA sequencing and gene-knockout mouse models to find ITGB6 mediating differential responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of the CX3CL1–CX3CR1 axis in PF4+ macrophage–driven resistance?",{"text":121,"@type":113},"ITGB6 regulates CX3CL1, which recruits and activates PF4+ macrophages expressing high CX3CR1; inhibiting this axis suppresses macrophage infiltration and reduces CXCL16 secretion.",{"name":123,"@type":110,"acceptedAnswer":124},"How does PF4+ macrophage modulation affect CD8+ T cells and treatment sensitivity?",{"text":125,"@type":113},"Reducing CXCL16 infiltration and secretion reinvigorates cytotoxic CXCR6+ CD8+ T cells, enhancing sensitivity to anti-CD276 therapy and restoring responsiveness to PD1 antibodies in resistant mice.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},338068,1790974872,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article [https://doi.org/10.1038/s41467-024-51096-0](https://doi.org/10.1038/s41467-024-51096-0)  \nITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage inﬁltration  \nReceived: 3 November 2023  \n\n| Accepted: 30 July 2024 |\n| --- |\n| |\n| Check for updates |\n\nCaihua Zhang1,4, Kang Li1,4, Hongzhang Zhu 1,4, Maosheng Cheng1,4, Shuang Chen1, Rongsong Ling 2, Cheng Wang 3 & Demeng Chen 1   \nEnoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efﬁcacy in activating T cells and oligodendrocyte-like cells against various cancers. Preclinical studies and mouse models suggest that therapies targeting CD276 may outperform PD1/PD-L1 blockade. However, data from mouse models indicate a signiﬁcant non-responsive population to anti-CD276 treatment, with the mechanisms of resistance still unclear. In this study, we evaluate the activity of anti-CD276 antibodies in a chemically-induced murine model of head and neck squamous cell carcinoma. Using models of induced and orthotopic carcinogenesis, we identify ITGB6 as a key gene mediating differential responses to anti-CD276 treatment. Through single-cell RNA sequencing and gene-knockout mouse models, we ﬁnd that ITGB6 regulates the expression ofthe tumor-associated chemokine CX3CL1, which recruits and activates PF4+ macrophages that express high levels of CX3CR1. Inhibition of the CX3CL1-CX3CR1 axis suppresses the inﬁltration and secretion of CXCL16 by PF4+ macrophages, thereby reinvigorating cytotoxic CXCR6+ CD8+ T cells and enhancing sensitivity to anti-CD276 treatment. Further investigations demonstrate that inhibiting ITGB6 restores sensitivity to PD1 antibodies in mice resistant to anti-PD1 treatment. In summary, our research reveals a resistance mechanism associated with immune checkpoint inhibitor therapy and identiﬁes potential targets to overcome resistance in cancer treatment.  \nImmune checkpoint inhibitors (ICIs), such as those targeting programmed cell death 1 (PD1) and its ligand (PD-L1) or cytotoxic T lymphocyte-associated protein 4 (CTLA4), have revolutionized solid tumor therapy, signiﬁcantly improving patient survival rates1,2. Compared to PD-L1, CD276 (B7 homolog 3 protein) is more robustly and speciﬁcally expressed in various epithelial-origin cancers, making it a promising target for anti-cancer therapy3. For instance, we have previously demonstrated that CD276 is enriched in the cancer stem cells (CSCs) of head and neck squamous cell carcinoma  \n(HNSCC) and can serve as a therapeutic target for HNSCC4,5. Moreover, multiple clinical trials have conﬁrmed the antitumor effectiveness and safety of enoblituzumab, a humanized Fcengineered CD276-targeting antibody, in patients with localized prostate cancer (PCa), advanced HNSCC, and non-small cell lung cancer (NSCLC)6,7. Despite the advancements in α-CD276-based immunotherapy, the response rates remain suboptimal, and the molecular mechanisms underlying this resistance are not yet fully understood8.  \n1Otorhinolaryngology Hospital, The First Afﬁliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. 2Institute for Advanced Study, Shenzhen University, Shenzhen, China. 3Hospital ofStomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School ofStomatology, SunYat-sen University, Guangzhou, China. 4These authors contributed equally: Caihua Zhang, Kang Li, Hongzhang Zhu, Maosheng Cheng.  \ne-mail: [chendm29@mail.sysu.edu.cn](chendm29@mail.sysu.edu.cn)  \nThe failure of the immune response is largely governed by the interaction between the immune system and solid tumors. Previous studies have suggested that the negative regulatory function of CD276 is achieved through its binding to receptors expressed on activated T cells, thereby inhibiting their proliferation and production of immunosuppressive cytokines9. Additionally, various studies have highlighted the critical role of myeloid innate immune cells, such as granulocytes, monocy","cbCaih5bQynYhp35","https://ap.wps.com/l/cbCaih5bQynYhp35","pdf",8785970,23,"English","# Introduction\n# Methods and Models\n# Key Findings: ITGB6-Dependent Chemokine Regulation\n# PF4+ Macrophage Effects on CD8+ T Cells\n# Therapeutic Implications for Anti-CD276 and Anti-PD1 Resistance","[{\"question\":\"What problem does the study address in anti-CD276 treatment for head and neck cancer?\",\"answer\":\"The study addresses a non-responsive population to anti-CD276 therapy in mouse models, where the resistance mechanisms were unclear.\"},{\"question\":\"How did the researchers identify ITGB6 as relevant to anti-CD276 resistance?\",\"answer\":\"They used induced and orthotopic carcinogenesis models, then applied single-cell RNA sequencing and gene-knockout mouse models to find ITGB6 mediating differential responses.\"},{\"question\":\"What is the role of the CX3CL1–CX3CR1 axis in PF4+ macrophage–driven resistance?\",\"answer\":\"ITGB6 regulates CX3CL1, which recruits and activates PF4+ macrophages expressing high CX3CR1; inhibiting this axis suppresses macrophage infiltration and reduces CXCL16 secretion.\"},{\"question\":\"How does PF4+ macrophage modulation affect CD8+ T cells and treatment sensitivity?\",\"answer\":\"Reducing CXCL16 infiltration and secretion reinvigorates cytotoxic CXCR6+ CD8+ T cells, enhancing sensitivity to anti-CD276 therapy and restoring responsiveness to PD1 antibodies in resistant mice.\"}]","ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration | PDF",1790021814,58,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30d772ecb92bc52064443b06947c83d0.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c430fc7069b83b11fc2c9a5fb16cf05e.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea1e2b32a288f7cd90c8ae5287746f81.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/777357cf7c9faac83ed2aaf15d45c240.webp",980,1301]